1. Focused Atorvastatin Therapy in Managed-Care Patients With Coronary Heart Disease and CKD 
Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J. Wilson, MD, Rana S. Fayyad, PhD, Andrea Zuckerman, MD, David P. Reed, MD 
American Journal of Kidney Diseases 
Volume 53, Issue 5, Pages (May 2009)
DOI: /j.ajkd
Copyright © 2009 National Kidney Foundation, Inc. Terms and Conditions

2. Figure 1
Study design and disposition of patients shows chronic kidney disease (CKD) status at baseline. Completed end-point assessments included patients who returned for the final visit, those who died during the study, and those who reported an end point during the study but were either lost to follow-up at the last patient visit or discontinued from the trial before study end. Partial end-point assessments included patients who did not complete the study for various reasons, including discontinuations for adverse events and such administrative issues as withdrawn consent, protocol violations, and loss to follow-up. *Most patients not randomly assigned failed to meet inclusion criteria requiring a history of heart disease. Abbreviation: eGFR, estimated glomerular filtration rate.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2009 National Kidney Foundation, Inc. Terms and Conditions

3. Figure 2
Mean percentages of change in serum lipid levels from baseline to end of study in patients with eGFR less than 60 mL/min/1.73 m2 (with chronic kidney disease [CKD]) and eGFR of 60 mL/min/1.73 m2 or greater (without CKD) receiving either focused atorvastatin therapy or usual care. *Mean atorvastatin dose was 40.5 mg/d. †Lipid values were available for n = 271 (with CKD, atorvastatin), n = 158 (with CKD, usual care), n = 876 (without CKD, atorvastatin), and n = 568 (without CKD, usual care) patients. ‡P favors usual care. Abbreviations: HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LS-mean, least-squares mean; TGs, triglycerides; Total-C, total cholesterol.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2009 National Kidney Foundation, Inc. Terms and Conditions

4. Figure 3
Kaplan-Meier estimates for time to first primary outcome in patients with estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m2 (with chronic kidney disease [CKD]) and eGFR of 60 mL/min/1.73 m2 or greater (without CKD). *Log-rank P. Abbreviations: CI, confidence interval; HR, hazard ratio.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2009 National Kidney Foundation, Inc. Terms and Conditions

5. Figure 4
Kaplan-Meier estimates for time to first primary outcome in patients with estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m2 (with chronic kidney disease [CKD]) and eGFR of 60 mL/min/1.73 m2 or greater (without CKD) receiving either focused atorvastatin therapy or usual care. *Mean atorvastatin dose was 40.5 mg/d. †Log-rank P. Abbreviations: CI, confidence interval; HR, hazard ratio.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2009 National Kidney Foundation, Inc. Terms and Conditions

6. Figure 5
Primary and secondary outcome event rates in patients with estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m2 (with chronic kidney disease [CKD]) and eGFR of 60 mL/min/1.73 m2 or greater (without CKD) receiving either focused atorvastatin therapy or usual care. *Mean atorvastatin dose was 40.5 mg/d. †Hazard ratio (HR) (95% confidence interval [CI]) and P by means of Cox proportional hazards model with center as a covariate. ‡Unstable angina requiring hospitalization. Abbreviations: CHF, congestive heart failure; MI, myocardial infarction.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2009 National Kidney Foundation, Inc. Terms and Conditions